# STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)

> **NCT02943590** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 300 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Placebo
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT02943590
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-13
- **Primary completion:** 2022-09-16
- **Final completion:** 2023-10-11
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2025-05-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02943590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02943590, "STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02943590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*